Your browser doesn't support javascript.
Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19.
Shahrbaf, Mohammad Amin; Tabary, Mohammadreza; Khaheshi, Isa.
  • Shahrbaf MA; Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Tabary M; Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
  • Khaheshi I; Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Cardiovasc Hematol Disord Drug Targets ; 21(2): 88-90, 2021.
Article in English | MEDLINE | ID: covidwho-1357470
ABSTRACT
After the outbreak of COVID-19, many novel drugs have been introduced to improve patients' conditions. Remdesivir and Favipiravir are among the most common drugs used against SARS-CoV-2. Although promising, cardiovascular side effects of these drugs should be considered by physicians and nurses. In this study, we searched databases for assessing the cardiovascular side effects of Remdesivir and Favipiravir. It seems that despite the beneficial effects of these drugs, due to the cardiovascular complications of COVID-19 and cardiovascular side effects of these drugs, which can overlap with each other, the use of these drugs can be a challenging issue in the cardiovascular practice.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pyrazines / Adenosine Monophosphate / Alanine / Amides / COVID-19 Drug Treatment / Heart Diseases Limits: Humans Language: English Journal: Cardiovasc Hematol Disord Drug Targets Journal subject: Vascular Diseases / Cardiology / Hematology / Drug Therapy Year: 2021 Document Type: Article Affiliation country: 1871529X21666210812103535

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Pyrazines / Adenosine Monophosphate / Alanine / Amides / COVID-19 Drug Treatment / Heart Diseases Limits: Humans Language: English Journal: Cardiovasc Hematol Disord Drug Targets Journal subject: Vascular Diseases / Cardiology / Hematology / Drug Therapy Year: 2021 Document Type: Article Affiliation country: 1871529X21666210812103535